Osmosis Investment Management UK Ltd bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 3,638 shares of the biopharmaceutical company’s stock, valued at approximately $1,095,000.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Sanctuary Advisors LLC acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $945,000. Polymer Capital Management HK LTD acquired a new stake in Alnylam Pharmaceuticals during the second quarter worth about $19,554,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Alnylam Pharmaceuticals in the second quarter valued at approximately $200,000. Meiji Yasuda Asset Management Co Ltd. purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $327,000. Finally, Bank of Nova Scotia purchased a new stake in Alnylam Pharmaceuticals in the 2nd quarter worth approximately $2,447,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.
Alnylam Pharmaceuticals Trading Down 0.1%
ALNY opened at $236.01 on Tuesday. The firm has a market capitalization of $31.58 billion, a price-to-earnings ratio of 43.87 and a beta of 0.30. The company’s 50 day simple moving average is $265.98 and its two-hundred day simple moving average is $296.21. Alnylam Pharmaceuticals, Inc. has a 1-year low of $197.81 and a 1-year high of $495.55. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99.
Insider Buying and Selling
In other Alnylam Pharmaceuticals news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $299.18, for a total value of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares in the company, valued at $473,302.76. The trade was a 70.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.86% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
Several equities analysts have recently weighed in on the stock. Citigroup cut their target price on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a report on Monday, August 3rd. HC Wainwright dropped their price target on shares of Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. BMO Capital Markets started coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, August 19th. They issued an “outperform” rating and a $318.00 price objective for the company. Needham & Company LLC lowered their target price on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating on the stock in a research note on Thursday, July 30th. Finally, Barclays cut their price target on Alnylam Pharmaceuticals from $527.00 to $450.00 and set an “overweight” rating for the company in a research note on Monday, August 3rd. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $386.62.
Get Our Latest Stock Report on Alnylam Pharmaceuticals
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.
Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.
Featured Articles
- Five stocks we like better than Alnylam Pharmaceuticals
- Visa Just Put Hims & Hers in the Penalty Box—Here’s Why It Matters
- Treasury Yields Are Surging Again: 3 Stocks That Could Feel the Pain
- Snowflake Could Be Headed for New Highs Despite Insider Selling
- MongoDB Is Surging—And the Next Catalyst Is Almost Here
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
